Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPLA Study: Convalescent Plasma for Severe COVID-19
NCT04357106Phase 2Unknown
- Sponsor
- Centro de Hematología y Medicina Interna
- Start
- Apr 2020
- Primary completion
- Jul 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19), sponsored by Centro de Hematología y Medicina Interna. Primary endpoints: Lung injury at 7 days and Overall Survival. Status: unknown.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04357106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04357106.